Dr. Kimme Hyrich Discusses Cancer Risk in RA Patients Receiving Anti-TNF Therapies
Feb 22, 2012 |
Kimme L. Hyrich, MD, Arthritis Research UK Epidemiology Unit at University of Manchester, discusses the risk of rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy developing solid cancers.
“When they were first used and available for widespread use, there was a continuing anxiety about whether or not an agent which blocks tumor necrosis factor would actually increase the risk of cancer in patients with rheumatoid arthritis,” said Hyrich.
Rheumatoid arthritis pain has been alleviated in half of patients enrolled in a study which used an electrical implanted device to emit magnetic pulses at the Academic Medical Center in Amsterdam, the Netherlands.
For patients with chronic lymphocytic leukemia, the Bruton tyrosine kinase inhibitor ibrutinib is effective, and prognosis is poor after discontinuation, according to a study published online Feb. 26 in JAMA Oncology. The research identifies, for the first time, baseline factors associated with ibrutinib therapy discontinuation.
Patients with metastatic colorectal cancer that started on the left side may be more likely to survive than those whose disease originated on the right side, according to research published in the March issue of the Journal of the National Cancer Institute.
US recommendations against the prostate-specific antigen test for prostate cancer might have prompted a small but measurable increase in the number of higher-risk cases diagnosed recently, according to a new study. Findings from the study are to be presented Thursday at the American Society of Clinical Oncology's annual Genitourinary Cancers Symposium, held from Feb. 26 to 28 in Orlando, Fla.